Former ActiveHealth executive shifts to CVS Caremark’s PBM unit
WOONSOCKET, R.I. CVS Caremark announced the appointment of Len Greer to the position of SVP marketing for its pharmacy benefit management business. Greer assumes responsibility for the company’s PBM marketing from Jack Bruner, who is transitioning to the new role of EVP strategic development.
Greer brings twenty years of experience in marketing, strategy and product development to CVS Caremark. He joins the company from ActiveHealth where he was the EVP marketing responsible for developing and implementing marketing strategies to drive brand awareness in the health plan and plan sponsor marketplace. Prior to his tenure with ActiveHealth, he spent six years at Medco Health in various senior marketing roles. Before joining Medco, Greer was a management consultant at McKinsey & Co., where he assisted clients on issues of marketing, strategy, product development and operations.
“Len’s analytical background, knowledge of the industry and strong marketing skills make him uniquely qualified to help deliver our messages effectively in the marketplace,” said Tom Ryan, CVS Caremark president, chairman and CEO.
Merck, Schering-Plough to complete merger
WHITEHOUSE STATION, N.J. Drug makers Merck & Co. and Schering-Plough Corp. will complete their merger Tuesday, Merck announced.
The two companies will begin combined operations Wednesday, with Schering-Plough adopting the Merck name and Schering-Plough stock becoming stock in the combined company.
The announcement of the merger follows recent clearance from regulatory authorities in China, Europe and Mexico, as well as the recent finalization of Pfizer’s acquisition of Wyeth.
Bristol-Myers Squibb on Baraclude: Better efficacy than competitor
BOSTON A Bristol-Myers Squibb drug used to treat hepatitis B kept viral load levels down more effectively than its competitor, according to study results announced by the company.
Bristol presented results in Boston Saturday at the American Association for the Study of Liver Disease’s annual meeting of a 48-week study comparing Baraclude (entecavir) with Gilead Sciences’ Hepsera (adefovir) in 191 patients with chronic hepatitis B infection with severe cirrhosis of the liver, also known as decompensated cirrhosis. Liver disease accounts for up to 25% of hepatitis B-related deaths.
Halfway through the study, 49% of 100 patients taking Baraclude had an undetectable viral load, compared with 16% of the 91 taking Hepsera. By the end of the study, 57% of Baraclude patients had an undetectable load, versus 20% of Hepsera patients.
“This study represents an important step in addressing an unmet medical need, as this is one of the first comparative studies to evaluate the safety and efficacy of antiviral therapy in this difficult-to-treat patient population,” said Hugo Cheinquer, study investigator and associate professor of gastroenterology and hepatology at the Universidade Federal do Rio Grande do Sul in Porto Alegre, Brazil. “Chronic hepatitis B is a lifelong disease, and these data suggest that treatment with Baraclude may offer chronic hepatitis B patients with decompensated cirrhosis a treatment option.”